Sci Transl Med 2014 Umegaki Arao 264ra164
Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa
Noriko Umegaki-Arao et al.
Sci Transl Med 6, 264ra164 (2014);
DOI: 10.1126/scitranslmed.3009342
Editor 's Summary
Epidermolysis bullosa (EB) is a rare, inherited skin disorder that causes such severe blistering that patients are often relegated to a delicate life in bandages. Like a patchwork quilt, the skin of a patient with EB can consist of both mutated skin cells (which cause the disease) and spontaneously genetically corrected ' 'normal ' ' cells; this patchwork phenomenon is known as revertant mosaicism. In a new study, Umegaki-Arao and colleagues demonstrated that these revertant cells could be used to generate healthy skin, representing a possible cell therapy for patients with EB who have no treatment options. The authors took revertant keratinocytes (skin cells) from a patient with junctional EB, who have mutations in the gene expressing type XVII collagen. These revertant keratinocytes were used to generate induced pluripotent stem cells, which, in turn, could be differentiated into a keratinocyte lineage that created normal-looking skin layers not only in vitro but also in vivo in mice. Because the cells already expressed type XVII collagen, there was no need for genetic correction, thus avoiding many of the pitfalls that gene and cell therapies face during translation to the clinic.
A complete electronic version of this article and other services, including high-resolution figures, can be found at: http://stm.sciencemag.org/content/6/264/264ra164.full.html Supplementary Material can be found in the online version of this article at: http://stm.sciencemag.org/content/suppl/2014/11/24/6.264.264ra164.DC1.html Related Resources for this article can be found online at: http://stm.sciencemag.org/content/scitransmed/6/264/264ra163.full.html http://stm.sciencemag.org/content/scitransmed/6/264/264ra165.full.html
Noriko Umegaki-Arao et al.
Sci Transl Med 6, 264ra164 (2014);
DOI: 10.1126/scitranslmed.3009342
Editor 's Summary
Epidermolysis bullosa (EB) is a rare, inherited skin disorder that causes such severe blistering that patients are often relegated to a delicate life in bandages. Like a patchwork quilt, the skin of a patient with EB can consist of both mutated skin cells (which cause the disease) and spontaneously genetically corrected ' 'normal ' ' cells; this patchwork phenomenon is known as revertant mosaicism. In a new study, Umegaki-Arao and colleagues demonstrated that these revertant cells could be used to generate healthy skin, representing a possible cell therapy for patients with EB who have no treatment options. The authors took revertant keratinocytes (skin cells) from a patient with junctional EB, who have mutations in the gene expressing type XVII collagen. These revertant keratinocytes were used to generate induced pluripotent stem cells, which, in turn, could be differentiated into a keratinocyte lineage that created normal-looking skin layers not only in vitro but also in vivo in mice. Because the cells already expressed type XVII collagen, there was no need for genetic correction, thus avoiding many of the pitfalls that gene and cell therapies face during translation to the clinic.
A complete electronic version of this article and other services, including high-resolution figures, can be found at: http://stm.sciencemag.org/content/6/264/264ra164.full.html Supplementary Material can be found in the online version of this article at: http://stm.sciencemag.org/content/suppl/2014/11/24/6.264.264ra164.DC1.html Related Resources for this article can be found online at: http://stm.sciencemag.org/content/scitransmed/6/264/264ra163.full.html http://stm.sciencemag.org/content/scitransmed/6/264/264ra165.full.html
References: Mechanisms of natural gene therapy. Discov. Med. 14, 167–179 (2012). 161, 444–447 (2009). 3. M. F. Jonkman, Revertant mosaicism in human genetic disorders. Am. J. Med. Genet. 85, 361–364 (1999). Genet. 14, 293–303 (1988). Dermatol. 70, 1103–1126 (2014). Ther. 21, 1299–1310 (2010). J. Tolar, TALEN-based gene correction for epidermolysis bullosa. Mol. Ther. 21, 1151–1159 (2013). dystrophic epidermolysis bullosa. J. Invest. Dermatol. 128, 2179–2189 (2008). J. Invest. Dermatol. 118, 626–630 (2002). Invest. 117, 1240–1248 (2007). Cell 88, 543–551 (1997). Hum. Genet. 77, 727–740 (2005). bullosa. J. Invest. Dermatol. 130, 1937–1940 (2010). Med. 360, 1680–1682 (2009). mutations. J. Invest. Dermatol. 132, 1374–1383 (2012). 23. L. T. Cheng, L. T. Sun, T. Tada, Genome editing in induced pluripotent stem cells. Genes Cells 17, 431–438 (2012). 24. A. Gostyński, A. M. Pasmooij, M. F. Jonkman, Successful therapeutic transplantation of revertant skin in epidermolysis bullosa. J. Am. Acad. Dermatol. 70, 98–101 (2014). collagen revertant cells in an animal model of revertant cell therapy. J. Invest. Dermatol. 134, 571–574 (2014). Acad. Sci. U.S.A. 108, 8797–8802 (2011). 1145–1147 (1998). 6, 264ra165 (2014). Downloaded from stm.sciencemag.org on December 1, 2014 RESEARCH ARTICLE PLOS One 8, e77673 (2013).